Double-blind comparison of fluoxetine versus clomipramine in the treatment of obsessive compulsive disorder

López-Ibor, Juan J; Sáiz, Jerónimo; Cottraux, Jean; Viñas, R; Bourgeois, M; Hernandez, Mariely; Gómez-Pérez, J.C.

doi:10.1016/0924-977x(95)00071-v

Cited by 68 publications

(31 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…fluoxetine, fluvoxamine, sertraline, paroxetine and citalopram) into the clinical practice has challenged the traditional concept of antidepressants and anxiolytics (Uhlenhuth et al 1999). In fact (Table 1), SSRIs, like tricyclics, have been shown to be effective not only in the treatment of depression (Baldessarini 1996b), but also in the treatment of PD (Gorman et al 1987;Westenberg 1988, 1990;Schneier et al 1990;Black et al 1993;Hoehn-Saric et al 1993;Oehrberg et al 1995;Coplan et al 1997;Wade et al 1997;Ballenger et al 1998;Gunasekara et al 1998;Kent et al 1998;Londborg et al 1998;Michelson et al 1998;Pohl et al 1998;Pollack et al 1998;Sandmann et al 1998;Hurst and Lamb 2000), OCD (Cottraux et al 1990;Pigott et al 1990;Goodman et al 1990Goodman et al , 1996Pigott et al 1992;Montgomery et al 1993;Wheadon et al 1993;Wood et al 1993;Freeman et al 1994;Tollefson et al 1994;Greist et al 1995;Koran et al 1996;Piccinelli et al 1995;Lopez-Ibor et al 1996;Zohar and Judge 1996;Jenike et al 1997;Milanfranchi et al 1997;Mundo et al 1997;Gunasekara et a...…”

Section: Introductionmentioning

confidence: 96%

“…Since this report, several papers on the effectiveness of tricyclics or mono amino oxidase inhibitors (MAOIs) in PD (Gloger et al 1981;Zitrin et al 1983;Nies 1984;Mavissakalian and Perel 1985;Munjack et al 1985;Charney et al 1986;Rizley et al 1986;Cassano et al 1988), obsessivecompulsive disorder (OCD) (Fernandez et al 1967;Reynghe De Vorie 1968;Yaryura-Tobias et al 1976;Montgomery 1980;Insel et al 1983;Volavka et al 1985;Zohar and Insel 1987;Leonard et al 1988Leonard et al , 1989De Veaugh-Geiss et al 1989;Katz et al 1990;Pigott et al 1990;Piccinelli et al 1995;Lopez-Ibor et al 1996;Zohar and Judge 1996;Milanfranchi et al 1997;Rouillon 1998), social anxiety disorder (SAD) and generalised anxiety disorder (GAD) (Pecknold et al 1982;Nies 1984;Hoehn-Saric et al 1988;McLeod et al 1990) have been published. Other anxiety disorders, particularly the post-traumatic stress disorder (PTSD), were not sufficiently treated with the antidepressants available at that time (Shestatzky et al 1986;Frank et al1988;Reiss et al 1989).…”

Section: Introductionmentioning

confidence: 97%

See 1 more Smart Citation

Do animal models of anxiety predict anxiolytic-like effects of antidepressants?

2002

View full text Add to dashboard Cite

Chronically administered antidepressant drugs, particularly selective serotonin (5-HT) reuptake inhibitors (SSRIs), are clinically effective in the treatment of all anxiety disorders, while the clinical effectiveness of "traditional" anxiolytics, such as benzodiazepines (BDZs), is limited to generalised anxiety disorder or acute panic attacks. This implies that animal models of anxiety should be sensitive to SSRIs and other antidepressants in order to have predictive validity. We reviewed the literature on the effects of antidepressants in the so-called animal models of anxiety and found that only the isolation-induced calls in guinea-pig pups may reveal anxiolytic-like action of all antidepressant classes after acute administration. Some other models, such as marble-burying or conditioned-freezing behaviours, and isolation- or shock-induced ultrasonic vocalisation models, may detect anxiolytic-like activity of acutely administered antidepressants, although the sensitivity of these models is usually limited to SSRIs and other drugs affecting 5-HT uptake. The predictive validity of models of "anxiety", such as the plus-maze and light-dark transition tests or stress-induced hyperthermia, appears to be limited to BDZ-related drugs. Far less work has been done on chronic administration of antidepressants in animal anxiety models. Unless and until such studies have been undertaken, the true predictive value of the anxiety models will remain unknown.

show abstract

Section: Introductionmentioning

confidence: 96%

Section: Introductionmentioning

confidence: 97%

Do animal models of anxiety predict anxiolytic-like effects of antidepressants?

2002

View full text Add to dashboard Cite

show abstract

“…Á Fluoxetine was superior to placebo in doubleblind studies Tollefson et al 1994;Zitterl et al 1999). In a comparison with clomipramine, efficacy for both drugs was comparable, with a minor advantage for clomipramine (Lopez-Ibor et al 1996). In a one-year DBPC study, only patients on the highest dose of fluoxetine (60 mg)…”

Section: Selective Serotonin Reuptake Inhibitors (Ssris)mentioning

confidence: 99%

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision

Bandelow

Zohar

Hollander

et al. 2008

The World Journal of Biological Psychiatry

718

410

View full text Add to dashboard Cite

In this report, which is an update of a guideline published in 2002 (Bandelow et al. 2002, recommendations for the pharmacological treatment of anxiety disorder, obsessive-compulsive disorder (OCD) and post-traumatic stress disorder (PTSD) are presented. Since the publication of the first version of this guideline, a substantial number of new randomized controlled studies of anxiolytics have been published. In particular, more relapse prevention studies are now available that show sustained efficacy of anxiolytic drugs. The recommendations, developed by the World Federation of Societies of Biological Psychiatry (WFSBP) Task Force for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders, a consensus panel of 30 international experts, are now based on 510 published randomized, placebo-or comparator-controlled clinical studies (RCTs) and 130 open studies and case reports. First-line treatments for these disorders are selective serotonin reuptake inhibitors (SSRIs), serotonin-noradrenaline reuptake inhibitors (SNRIs) and the calcium channel modulator pregabalin. Tricyclic antidepressants (TCAs) are equally effective for some disorders, but many are less well tolerated than the SSRIs/ SNRIs. In treatment-resistant cases, benzodiazepines may be used when the patient does not have a history of substance abuse disorders. Potential treatment options for patients unresponsive to standard treatments are described in this overview. Although these guidelines focus on medications, non-pharmacological were also considered. Cognitive behavioural therapy (CBT) and other variants of behaviour therapy have been sufficiently investigated in controlled studies in patients with anxiety disorders, OCD, and PTSD to support them being recommended either alone or in combination with the above medicines.

show abstract

“…Actually, there have been relatively few comparative studies between the SSRIs in the treatment of OCD [20, 21, 22]. The studies comparing SSRI and clomipramine have shown that they all demonstrated efficacy [23, 24]. However, clomipramine is also associated with an increased incidence of adverse effects [25, 26, 27, 28, 29].…”

Section: Therapeutic Strategiesmentioning

confidence: 99%